A new batch of data for Gilead Sciences’ remdesivir points to efficacy but it’s no ‘silver bullet’

A new batch of data for Gilead Sciences’ remdesivir points to efficacy but it’s no ‘silver bullet’

A slice of data from the third clinical trial for Gilead Sciences Inc.’s remdesivir indicates that the experimental therapy is somewhat effective in treating COVID-19 patients but is not the silver bullet that had been hoped for.

Read More…

You May Also Like